Data Sheet 1_Treatment with pemafibrate ameliorates fatty liver index and atherogenic lipid profiles in Japanese patients with type 2 diabetes mellitus.pdf

Background<p>Pemafibrate, a selective peroxisome proliferator-activated receptor α modulator, ameliorates hypertriglyceridemia. We investigated the effects of pemafibrate on steatotic liver disease (SLD) in relation to various atherogenic lipid profiles.</p>Methods<p>Thirty-nine Ja...

Full description

Saved in:

Bibliographic Details
Main Author:	Toru Suzuki (512729) (author)
Other Authors:	Tatsuya Sato (317466) (author), Marenao Tanaka (339815) (author), Kei Nakata (4694041) (author), Keisuke Endo (3699778) (author), Hiroki Aida (21730937) (author), Wataru Kawaharata (21730940) (author), Itaru Hosaka (20527517) (author), Araya Umetsu (3463946) (author), Toshifumi Ogawa (20527520) (author), Yukinori Akiyama (14670614) (author), Masato Furuhashi (85555) (author)
Published:	2025
Subjects:	Cell Metabolism pemafibrate fatty liver index metabolic dysfunction-associated steatotic liver disease type 2 diabetes atherogenic lipid profiles
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Data Sheet 1_Treatment with pemafibrate ameliorates fatty liver index and atherogenic lipid profiles in Japanese patients with type 2 diabetes mellitus.pdf

Similar Items